← Leaderboards
Simeon I Taylor
University Of Maryland Baltimore
$9,588,026
Attributed
$14,692,717
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2015–25$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,420,032 · 9
By mechanism
P30$8,225,785 · 3
R01$6,924,938 · 3
U01$2,477,577 · 1
T32$2,369,607 · 1
R21$422,125 · 1
Top collaborators
- Amber L Beitelshees10 shared
- Braxton D Mitchell10 shared
- May Montasser2 shared
- Elif Arioglu Oral1 shared
- Richard E Pratley1 shared
- Michael J. Quon1 shared
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- Amber L Beitelshees$6,724,440
- Edward J Weinman$4,634,345
- Norann Amir Zaghloul$1,719,991
- Toni I. Pollin$9,434,908
- Sarah Robbins$67,402
Others in their field
Top investigators on “Diabetes Mellitus”
- Jeffrey P Krischer · University Of South Florida$608,226,434
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$177,347,135
- John M Lachin · George Washington University$155,262,668
- David M Nathan · Massachusetts Institute Of Technology$142,806,023
- Judith S Hochman · New York University School Of Medicine$100,149,457
- Jose A Luchsinger · Columbia University Health Sciences$75,551,718
Research focus
Diabetes MellitusAmericanProgramsObesityGeneticMetabolicPhysiologicalBaseReportingAmishGenesDiet And ExerciseInsightResponseGenetic VariantPharmaceutical PreparationsNon-Insulin-Dependent Diabetes MellitusGlucoseMediatingClinical ResearchAdultDiabetic PatientEventFunctional Disorder
Grant awards (46)
Ketone Monitoring Approaches for DKA Risk Mitigation in People with T1D on Adjunctive SGLT2 Inhibitors (KARMA)$2,477,577
U01 · FY2025 · DK
Tirzepatide for treatment of familial partial lipodystrophy$793,098
R01 · FY2025 · DK
Pharmacogenetics of the Response to a GLP1R Agonist$604,825
R01 · FY2025 · DK
Diabetes, Obesity, and Metabolic Complications$274,380
T32 · FY2025 · DK · contact PI
Pharmacogenetics of the Response to a GLP1R Agonist$645,147
R01 · FY2024 · DK
Diabetes, Obesity, and Metabolic Complications$243,542
T32 · FY2024 · DK · contact PI
Pharmacogenetics of the Response to a GLP1R Agonist$672,029
R01 · FY2023 · DK
Diabetes, Obesity, and Metabolic Complications$208,630
T32 · FY2023 · DK · contact PI
Pharmacogenetics of the Response to a GLP1R Agonist$672,029
R01 · FY2022 · DK · contact PI
Genetics of Response to Canagliflozin$639,301
R01 · FY2022 · DK
Diabetes, Obesity, and Metabolic Complications$245,095
T32 · FY2022 · DK · contact PI
Genetics of Response to Canagliflozin$677,220
R01 · FY2021 · DK · contact PI
Diabetes, Obesity, and Metabolic Complications$267,558
T32 · FY2021 · DK · contact PI
Genetics of Response to Canagliflozin$682,434
R01 · FY2020 · DK · contact PI
Mid-Atlantic Nutrition Obesity Research Center$1,140,113
P30 · FY2019 · DK · contact PI
Genetics of Response to Canagliflozin$689,388
R01 · FY2019 · DK · contact PI
Administrative, Biostatistics and Enrichment Core$462,800
P30 · FY2019 · DK · contact PI
Diabetes and its Metabolic Complications$178,346
T32 · FY2019 · DK · contact PI
Do vitamin D supplements protect against adverse effect of canagliflozin on bone health?$154,377
R01 · FY2019 · DK · contact PI
Research Base$31,544
P30 · FY2019 · DK · contact PI
Mid-Atlantic Nutrition Obesity Research Center$1,140,113
P30 · FY2018 · DK · contact PI
Genetics of Response to Canagliflozin$695,090
R01 · FY2018 · DK · contact PI
Administrative, Biostatistics and Enrichment Core$462,800
P30 · FY2018 · DK · contact PI
Diabetes and its Metabolic Complications$172,834
T32 · FY2018 · DK · contact PI
Diabetes and its Metabolic Complications$69,341
T32 · FY2018 · DK · contact PI
Research Base$31,544
P30 · FY2018 · DK · contact PI
Mid-Atlantic Nutrition Obesity Research Center$1,140,113
P30 · FY2017 · DK · contact PI
Administrative, Biostatistics and Enrichment Core$462,800
P30 · FY2017 · DK · contact PI
Diabetes and its Metabolic Complications$165,601
T32 · FY2017 · DK · contact PI
Diabetes and its Metabolic Complications$65,669
T32 · FY2017 · DK · contact PI
Research Base$31,544
P30 · FY2017 · DK · contact PI
Diabetes and its Metabolic Complications$3,498
T32 · FY2017 · DK · contact PI
Mid-Atlantic Nutrition Obesity Research Center$1,140,113
P30 · FY2016 · DK · contact PI
Administrative, Biostatistics and Enrichment Core$462,800
P30 · FY2016 · DK · contact PI
Diabetes and its Metabolic Complications$212,801
T32 · FY2016 · DK · contact PI
Pharmacogenomics of SGLT2 inhibitors: Pilot & Feasibility Study$191,875
R21 · FY2016 · DK · contact PI
Diabetes and its Metabolic Complications$61,184
T32 · FY2016 · DK · contact PI
Research Base$31,544
P30 · FY2016 · DK · contact PI
Mid-Atlantic Nutrition Obesity Research Center$1,166,863
P30 · FY2015 · DK · contact PI
Administrative, Biostatistics and Enrichment Core$489,550
P30 · FY2015 · DK · contact PI
Pharmacogenomics of SGLT2 inhibitors: Pilot & Feasibility Study$230,250
R21 · FY2015 · DK · contact PI
Diabetes and its Metabolic Complications$201,128
T32 · FY2015 · DK · contact PI
Research Base$31,544
P30 · FY2015 · DK · contact PI
INSULIN RECEPTORS AND MOLECULAR MECHANISMS OF INSULIN ACTION$0
Z01 · FY2000 · DK
Sorting Nexins and Intracellular Protein Trafficking$0
Z01 · FY2000 · DK
MOLECULAR GENETICS OF INSULIN RESISTANCE AND NONINSULIN-DEPENDENT DIABETES$0
Z01 · FY2000 · DK